Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

384 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. King B, et al. J Am Acad Dermatol. 2021 Aug;85(2):379-387. doi: 10.1016/j.jaad.2021.03.050. Epub 2021 Mar 20. J Am Acad Dermatol. 2021. PMID: 33757798 Free article. Clinical Trial.
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.
Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Rose S, Jim On S, Li X, Fuentes-Duculan J, Estrada Y, Garcet S, Traidl-Hoffmann C, Krueger JG, Lebwohl MG. Guttman-Yassky E, et al. J Am Acad Dermatol. 2018 May;78(5):872-881.e6. doi: 10.1016/j.jaad.2018.01.016. Epub 2018 Jan 17. J Am Acad Dermatol. 2018. PMID: 29353025 Free PMC article. Clinical Trial.
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, de la Peña A, Nunes FP, Janes J, Gamalo M, Donley D, Paik J, DeLozier AM, Nickoloff BJ, Simpson EL. Guttman-Yassky E, et al. J Am Acad Dermatol. 2019 Apr;80(4):913-921.e9. doi: 10.1016/j.jaad.2018.01.018. Epub 2018 Feb 2. J Am Acad Dermatol. 2019. PMID: 29410014 Clinical Trial.
Serum from Asian patients with atopic dermatitis is characterized by TH2/TH22 activation, which is highly correlated with nonlesional skin measures.
Wen HC, Czarnowicki T, Noda S, Malik K, Pavel AB, Nakajima S, Honda T, Shin JU, Lee H, Chou M, Estrada Y, Zheng X, Xu H, Krueger JG, Lee KH, Kabashima K, Guttman-Yassky E. Wen HC, et al. J Allergy Clin Immunol. 2018 Jul;142(1):324-328.e11. doi: 10.1016/j.jaci.2018.02.047. Epub 2018 Apr 11. J Allergy Clin Immunol. 2018. PMID: 29653116 No abstract available.
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab.
Brunner PM, Pavel AB, Khattri S, Leonard A, Malik K, Rose S, Jim On S, Vekaria AS, Traidl-Hoffmann C, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Fuentes-Duculan J, Li X, Zheng X, Estrada Y, Garcet S, Wen HC, Gonzalez J, Coats I, Cueto I, Neumann AU, Lebwohl MG, Krueger JG, Guttman-Yassky E. Brunner PM, et al. J Allergy Clin Immunol. 2019 Jan;143(1):142-154. doi: 10.1016/j.jaci.2018.07.028. Epub 2018 Aug 17. J Allergy Clin Immunol. 2019. PMID: 30121291 Clinical Trial.
384 results